Blood plasma product is the extracted portion from the blood using fractionation process to deliver products rich in plasma proteins. These products are used as body fluids, antibodies and clotting factors in medical industries that aid in treatment of chronic ailments like auto-immune disorders and haemophilia. The global blood plasma product market is expected to witness a significant growth during the forecast period due to the high demand by a large pool of patients with no alternative therapeutic approach. Blood plasma product have a wide range of components that have clinical use such as, Albumin, Factor VIII, Factor IX, immunoglobulin, fibrinogen with their major applications in bleeding disorders (haemophilia, immunological disorders), massive hemorrhage and in traumatic injuries. Moreover, the presence of biomarkers in plasma adds to their application in clinical diagnosis of diseases. These factors will drive the growth of global blood plasma product market in future.
Stringent regulatory standards on the import and export of plasma product hinder the growth of the global blood plasma product market. Other restraining factors includes the high complexity and cost associated with the collection of blood plasma, and dearth of trained and skilled professionals for fractionation process.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=blood-plasma-product-market
The identification of new proteins in blood plasma to be used as therapeutic products are under clinical investigation. This will provide opportunity to companies to maximize the volume of blood plasma fractionation. Further, exploring novel therapeutic application of the known blood plasma product to be used for other diseases will also provide ample opportunities to the market players to invest and expand in the global market.
The key players across the globe, are acquiring companies and units to enhance their portfolio and spreading geographically to gain large shares in the global blood plasma product market.
In June 2017, CSL Ltd., announced its first acquisition in Chinese market by acquiring Wuhan Zhong Yuan Rui De Biological Products Co. Ltd., a subsidiary of Humanwell Healthcare Co. Ltd. This will expand CSL Ltd. plasma collection and product portfolio in Asia Pacific’s blood plasma product market.
The other key players in the global market are Shire Pls., Octapharma AG, Kedrion S.p.A, Biotest AG, China Biologic Products, Inc., Sanquin and LFB S.A.